Evidence map›Paper›PMID 34679246›Full record

ArticleCurrent protocols2021

Protocols for Characterization of Cdk5 Kinase Activity.

Anita Terse, Niranjana Amin, Bradford Hall, Manju Bhaskar, Binukumar B K, Elias Utreras, Tej K Pareek, Harish Pant, Ashok B Kulkarni

Open access · greenAbstract read
In one paragraph

Article in Current protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Anita TerseNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
Niranjana AminNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Bradford HallNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
Manju BhaskarNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Binukumar B KCSIR-Institute of Genomics and Integrative Biology (IGIB), New Delhi, India.
Elias UtrerasDepartment of Biology, Universidad de Chile, Santiago, Chile.
Tej K PareekCelloram Inc., Beachwood, Ohio.
Harish PantNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Ashok B KulkarniNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
National Institutes of Health · USNational Institute of Dental and Craniofacial Research · USInstitute of Genomics and Integrative Biology · INThink A Move (United States) · USUniversidad de Santiago de Chile · CL

Funding

PHOSPHORYLATION OF NEURONAL CYTOSKELETON IN NEURODEGENERATIVE DISEASESZ01DE000664 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI KULKARNI, ASHOK B. · 1996 to 2008
$1.5M
Council of Scientific & Industrial ResearchIntramural NIH HHS Z01 DE000664NIDCR NIH HHSNIH HHSScience and Engineering Research Board
6 · The paper itself

Abstract

Cyclin-dependent kinases (Cdks) are generally known to be involved in controlling the cell cycle, but Cdk5 is a unique member of this protein family for being most active in post-mitotic neurons. Cdk5 is developmentally important in regulating neuronal migration, neurite outgrowth, and axon guidance. Cdk5 is enriched in synaptic membranes and is known to modulate synaptic activity. Postnatally, Cdk5 can also affect neuronal processes such as dopaminergic signaling and pain sensitivity. Dysregulated Cdk5, in contrast, has been linked to neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Despite primarily being implicated in neuronal development and activity, Cdk5 has lately been linked to non-neuronal functions including cancer cell growth, immune responses, and diabetes. Since Cdk5 activity is tightly regulated, a method for measuring its kinase activity is needed to fully understand the precise role of Cdk5 in developmental and disease processes. This article includes methods for detecting Cdk5 kinase activity in cultured cells or tissues, identifying new substrates, and screening for new kinase inhibitors. Furthermore, since Cdk5 shares homology and substrate specificity with Cdk1 and Cdk2, the Cdk5 kinase assay can be used, with modification, to measure the activity of other Cdks as well. © 2021 Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA. Basic Protocol 1: Measuring Cdk5 activity from protein lysates Support Protocol 1: Immunoprecipitation of Cdk5 using Dynabeads Alternate Protocol: Non-radioactive protocols to measure Cdk5 kinase activity Support Protocol 2: Western blot analysis for the detection of Cdk5, p35, and p39 Support Protocol 3: Immunodetection analysis for Cdk5, p35, and p39 Support Protocol 4: Genetically engineered mice (+ and - controls) Basic Protocol 2: Identifying new Cdk5 substrates and kinase inhibitors.

Indexed as

Cyclin-Dependent Kinase 5NeuronsAnimalsAxon GuidanceMiceNeurogenesisPhosphorylationSignal TransductionCyclin-Dependent Kinase 5Cdk5kinase assayp25p35p39

Identifiers

PMID34679246
PMCPMC8555461
OpenAlexW3206175053

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.